L-[1-13C]phenylalanine breath test in patients with chronic liver disease of different etiologies.
The aim of this study was to compare the oxidation of L-[1-(13)C]phenylalanine ((13)C-PheOx) in patients with chronic liver failure due to different etiologies using L-[1-(13)C]phenylalanine breath test. Breath samples were collected before the administration of 100 mg L-[1-(13)C]phenylalanine, and every 10 min thereafter until completion of 1 h. Control subjects (n=9) presented a larger cumulative percentage of (13)C dose recovery (CPDR) than patients (n=124) with chronic liver disease, regardless of the etiology (7.5+/-0.7 vs. 4.2+/-0.2, p=0.001). No differences in CPDR were found considering the Child-Pugh (CP) class or etiology: alcoholic (CP A=7.7+/-0.7, CP B=4.1+/-0.5, CP C=2.0+/-0.3), hepatitis C virus (CP A=5.4+/-0.5, CP B=4.0+/-0.2, CP C=2.2+/-0.3), hepatocellular carcinoma (CP A=5.5+/-1.6, CP B=3.6+/-1.8, CP C=2.2+/-1.0); or cryptogenic cirrhotic patients (CP A=7.4+/-1.5, CP B=4.4+/-0.4, CP C=2.1+/-0.7). Results confirm that (13)C-PheOx decreases in patients with cirrhosis with respect to controls, notwithstanding the etiology.
Moran
Segundo
S
Medical Center Siglo XXI, Mexican Institute of Social Security, Mexico, D.F., Mexico. segundomoran@hotmail.com
Gallardo-Wong
Irazu
I
Rodriguez-Leal
Gustavo
G
McCollough
Paulina
P
Mendez
Jorge
J
Castaneda
Beatriz
B
Milke
Pilar
P
Jacobo
Janet
J
Dehesa
Margarita
M
D001944:Breath Tests; D002247:Carbon Isotopes; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D005260:Female; D006526:Hepatitis C / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism*; D008108:Liver Diseases, Alcoholic / Q000378:metabolism; D008113:Liver Neoplasms / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010649:Phenylalanine / Q000032:analysis*; D013997:Time Factors
D002247:Carbon Isotopes; D010649:Phenylalanine